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Abstract: Platelets are involved in tumor angiogenesis and cancer progression. Previous studies
indicated that cancer could affect platelet content. In the current study, we investigated whether
cancer-associated proteins can be discerned in the platelets of cancer patients, and whether antitumor
treatment may affect the platelet proteome. Platelets were isolated from nine patients with different
cancer types and ten healthy volunteers. From three patients, platelets were isolated before and after
the start of antitumor treatment. Mass spectrometry-based proteomics of gel-fractionated platelet
proteins were used to compare patients versus controls and before and after treatment initiation. A
total of 4059 proteins were detected, of which 50 were significantly more abundant in patients, and
36 more in healthy volunteers. Eight of these proteins overlapped with our previous cancer platelet
proteomics study. From these data, we selected potential biomarkers of cancer including six upregu-
lated proteins (RNF213, CTSG, PGLYRP1, RPL8, S100A8, S100A9) and two downregulated proteins
(GPX1, TNS1). Antitumor treatment resulted in increased levels of 432 proteins and decreased levels
of 189 proteins. In conclusion, the platelet proteome may be affected in cancer patients and platelets
are a potential source of cancer biomarkers. In addition, we found in a small group of patients that
anticancer treatment significantly changes the platelet proteome.
Keywords: platelets; biomarkers; cancer; antitumor therapy; proteomics
1. Introduction
Survival of most patients with cancer is dependent on early discovery of the ma-
lignancy and treatment at an early stage [1]. Blood biomarkers of cancer could assist
physicians in discovery of the disease, and in making clinical decisions throughout anti-
tumor treatment. Until now, only a few clinically relevant cancer biomarkers have been
discovered [2–4]. Thus far, most researchers have focused on biomarkers in serum or
plasma of patients with regard to the presence or absence of cancer or the effect of therapy.
We proposed that platelets, which contain vast amounts of proteins, could serve as a new
source in the search for cancer biomarkers [5,6].
Platelets play an important role in primary hemostasis [7], inflammation [8], (tumor)
angiogenesis [9,10] and cancer metastasis [11]. In addition, there are several studies which
indicate that platelets could be of importance in the search for biomarkers of early-stage
cancer [12]. Platelets, which are produced by megakaryocytes in the bone marrow, contain
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numerous proteins that bring about change (e.g., growth factors, chemokines and proteases).
These proteins are either synthesized by the parental megakaryocytes or absorbed from the
(micro)circulation [9,13,14]. Besides proteins, platelets are also able to sequester drugs such
as bevacizumab [15] and sunitinib [16]. In addition, upon activation, platelets are able to
secrete their diverse content [17], which enables affecting (tumor) angiogenesis [9,10,18,19],
cancer cell proliferation [20] and migration [21] and metastasis [22,23].
Studies in mice demonstrate that the presence of a human tumor xenograft affects
platelet proteins with angiogenic or angiostatic functions, whilst their plasma levels did
not change [14,24,25]. Therefore, it was postulated that changes in platelet protein content
might indicate the presence or recurrence of a malignancy. While numerous studies in can-
cer patients identified thrombocytosis as a predictor of poor prognosis [26], human studies
investigating the effect of tumor presence on platelet characteristics and platelet content are
rare. We demonstrated that several platelet characteristics, as well as the platelet proteome,
are changed in patients with early-stage lung or pancreatic cancer [27,28]. Furthermore, we
showed that a combination of these changes could be exploited to discriminate patients
with early-stage disease from healthy sex- and age-matched individuals.
The aim of our current study was (1) to identify potential biomarkers of cancer that
could be used to discriminate cancer patients from healthy individuals, and (2) to explore
the effect of cancer therapy on the platelet proteome. We included patients with a variety
of cancer types and healthy controls. Using global protein profiling by mass spectrometry-
based proteomics, we demonstrated that the platelet proteome is not only affected by
cancer presence, but may also be affected by antitumor therapy.
2. Results
2.1. Comparison of Protein Content of Platelets of Cancer Patients versus Healthy Individuals
The platelet protein content of patients with cancer was compared to healthy volun-
teers to investigate whether cancer-associated proteins could be distilled. Prior to therapy
or after progressive disease following prior antitumor treatment, platelets from nine pa-
tients with different tumor types were isolated, washed and processed for proteomics
(Figure 1). The tumor types included colon, rectal, anal, esophageal, gastric, tongue and
primitive neuroectodermal cancer.
In addition, from ten healthy volunteers, platelets were isolated and processed at
the same time. Additionally, from three patients, a second sample was collected during
therapy to study the effect of antitumor therapy on the platelet proteome. Table 1 shows
the characteristics of the patients and healthy controls. The median ages of patients and
controls were 61 and 52 years, respectively. The comedication of the volunteers was
not available.
Platelet lysate samples were pre-fractionated by gel electrophoresis (Supplemental
Figure S1). The proteins were in-gel digested with trypsin and analyzed on a nanoLC-
MS/MS platform including a Q Exactive orbitrap mass spectrometer. Database searching
identified 4200 protein groups linked to 4059 unique proteins (Supplemental Table S1),
with an average of 2912 identified proteins in patient samples and 2808 in healthy control
samples. As a quantitative measure for protein abundance, we used spectral counting [29].
One hundred and eighteen unique proteins were significantly different in abundance
(p < 0.05) in samples of patients with cancer compared to healthy controls (Supplemental
Table S2).
Unsupervised hierarchical cluster analysis and principal component analysis using
normalized spectral count data do not show clear clustering of samples (Supplemental
Figure S2), whereas hierarchical clustering using differential proteins did show a clear
separation of cancer patients from all but one healthy control (Figure 2).




Figure 1. Schematic representation of the workflow. Blood was collected in citrated tubes. Platelet-rich 
plasma (PRP) was prepared by centrifugation. ACD was added, after which a platelet pellet was obtained 
by centrifugation. The pellet was resuspended in Hepes-Tyrode (HT) buffer (pH 6.5). Prostacyclin (PGI2) 
was added and a pellet was obtained by centrifugation. This was repeated once. Platelets were resus-
pended in HT buffer (pH 7.3). Tubes were centrifuged in the presence of PGI2. The pellet was resus-
pended in sample buffer, heated for 5 min at 99 °C and stored at −20 °C. Proteins were separated with 
electrophoresis (125 V) in precast gradient gels. In-gel digestion was performed. 
Table 1. Characteristics of the patients and healthy volunteers. Radiofrequency ablation (RFA), radiotherapy (RT), carpal 
tunnel syndrome (CTS), (paroxysmal) atrial fibrillation ((P)AF), benign prostatic hyperplasia (BPH), coronary artery by-
pass graft (CABG), percutaneous transluminal coronary angioplasty (PTCA) (* platelet counts one day before or after 
collection, ** platelet counts 2.5 months before and 1.5 month after sample collection). 
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Table 1. Characteristics of the patients and healthy volunteers. Radiofrequency ablation (RFA), radiotherapy (RT), carpal
tunnel syndrome (CTS), (paroxysmal) atrial fibrillation ((P)AF), benign prostatic hyperplasia (BPH), coronary artery bypass
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Figure 2. Platelet proteome profiling. Hierarchical clustering using proteins with differential abundance between platelets 
of patients with cancer (n = 9) and healthy controls (n = 10). 
Figure 2. Platelet proteome profiling. Hierarchical clustering using proteins with differential abundance between platelets
of patients with cancer (n = 9) and healthy controls (n = 10).
Fifty differential proteins were more than 1.5-fold more abundant in patients (Supple-
mental Table S3), and 36 more in healthy volunteers, respectively (Supplemental Table S4).
Twenty proteins were exclusively found in patients. Due to the heterogeneity of cancer
types and the low protein abundancies, these proteins were not detected in all patients.
2.2. Functional Analysis of Differential Proteins in Platelets of Cancer Patients and
Healthy Volunteers
To analyze the biological functions associated with the proteins that were significantly
different in abundance, we focused on the 50 and 36 proteins that were at least 1.5-fold
higher in abundance in patients and controls, respectively. Protein networks were created
using protein–protein association data from the STRING database [30], and visualized in
Cytoscape (Figure 3). In addition, gene ontology mining was performed using the BiNGO
Cytoscape app to identify underlying biological processes. Proteins with higher abundance
in cancer were mostly associated with inflammatory and immune responses (Figure 3A),
while in healthy controls these were mostly involved in amino acid metabolism (Figure 3B).
The networks were generated using default settings in String and visualized using Cytoscape.
2.3. Antitumor Treatment May Affect the Platelet Proteome of Cancer Patients
From three patients, platelet samples were collected both before and several weeks
after initiation of antitumor treatment. The protein content appeared to be considerably
different in samples collected on-treatment. A distinct difference in the band pattern on
the gel was observed compared to pre-treatment (Supplemental Figure S1). In addition,
hierarchical cluster analysis using differential proteins (paired statistics, p < 0.05) showed a
clear clustering of before- and on-treatment samples, respectively (Figure 4).
Antitumor therapy led to a significant change in expression of 713 platelet proteins,
with treatment leading to upregulation or downregulation of 432 and 189 proteins (>1.5-
fold), respectively (Supplemental Tables S5 and S6). The size of the major band observed
on gel in on-treatment samples is in line with that of HBB (hemoglobin beta chain, 16 kDa,
p = 0.006) and HBA1 (hemoglobin alpha 1, 15.3 kDa, p = 0.006). One hundred and fifty-
five proteins were uniquely identified on-treatment (Supplemental Table S7), and 35 only
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pre-treatment (Supplemental Table S8). Ten of the 621 proteins that were differential in the
treatment setting were among the 86 proteins that were differential in the comparison of
patients versus healthy volunteers.
The proteins being significantly higher in abundance after the start of antitumor
treatment (fold change > 5) (Figure 5) were generally linked to protein/RNA synthesis and
transport, RNA splicing and processing, DNA repair and telomere maintenance, gas/drug
transport and erythrocyte homeostasis, regulation of apoptosis, myeloid cell activation and
regulation of catabolism.
The proteins with a higher abundance before treatment compared to on-treatment
(Supplemental Figure S3) were linked mostly to mitochondrial organization and cellular
respiration. Combined, the above data show that antitumor treatment may change the
platelet proteome of patients.
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cancer, proteins that were significantly differential (>1.5-fold, p < 0.05) in both studies were 
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Figure 5. Protein–protein networks of significantly upregulated platelet proteins after the start of antitumor treatment.
Platelet protein content was compared in paired samples of patients with cancer (n = 3) which were drawn pretreatment
and after initiation of antitumor treatment. (p < 0.05, fold change ≥ 5). The networks were generated with cytoscape app
“ClusterONE”.
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2.4. Selection of Potential Platelet Biomarkers of Cancer
To find cancer-associated proteins in platelets, our data were compared to those from
a previously published paper from our group, in which the platelet proteome of patients
with early-stage lung or pancreatic cancer (n = 12) was compared to platelets of a healthy
sex- and age-matched control group (n = 11) [28]. The results of both studies displayed
many similarities, including a comparable number of identified unique proteins (4384
versus 4059) and a large overlap between the protein sets (72%). Additionally, the number
of platelet proteins that were significantly differential in cancer patients versus healthy
controls was similar in both studies (104 versus 118). In order to find potential biomarkers
of cancer, proteins that were significantly differential (>1.5-fold, p < 0.05) in both studies
were selected (Figure 6, Table 2).




Figure 6. Flowchart depicting the steps used to select the most promising cancer-associated proteins within platelets, of 
which eight overlapped with our previous cancer platelet proteomics study [28]. 
Table 2. List of cancer associated proteins in platelets. 
      Current Study Sabrkhany et al. 
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CTSG Cathepsin G 1511 3.69 0.025 2.89 0.012 
PGLYRP1 Peptidoglycan recognition protein 1 8993 10.14 0.013 Only in cancer 0.005 
RNF213 Ring finger protein 213 57674 1.81 0.043 1.70 0.005 
RPL8 Ribosomal protein L8 6132 12.71 0.038 Only in cancer 0.024 
S100A8 S100 calcium binding protein A8 6279 1.97 0.043 1.58 0.029 
S100A9 S100 calcium binding protein A9 6280 1.90 0.034 1.66 0.007 
GPX1 Glutathione peroxidase 1 2876 −1.38 0.008 −1.20 0.020 
TNS1 Tensin 1 7145 −2.93 0.001 −1.59 0.035 
Six of these proteins had a higher abundance in cancer patients than in healthy con-
trols (RNF213/ring finger protein 213; CTSG/cathepsin G; PGLYRP1/peptidoglycan recog-
nition protein 1; RPL8/ribosomal protein L8; S100A8/S100 calcium binding protein A8; 
S100A9/S100 calcium binding protein A9). Two proteins were found at higher levels in 
healthy controls (GPX1/glutathione peroxidase 1; TNS1/tensin 1). Two additional pro-
teins, AMDHD2/amidohydrolase domain-containing 2 and ERAP1/endoplasmic reticu-
lum aminopeptidase 1, were significantly differential in both studies, but with opposite 
directions of change. Therefore, RNF213, CTSG, PGLYRP1, RPL8, S100A8, S100A9, GPX1 
and TNS1 were identified as promising cancer-associated proteins which may provide 
non-invasive cancer biomarkers. 
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Table 2. List of cancer s t l ts.
Current Study Sabrkhany et al.
Gene Symbol Protein Name Entrez ID Change p-Value Fold Change p-Value
CTSG Cathepsin G 1511 3.69 0.025 2.89 0.012
PGLYRP1 Peptidoglycan recognition protein 1 8993 10.14 0.013 Only in cancer 0.005
RNF213 Ring finger protein 213 57674 1.81 0.043 1.70 0.005
RPL8 Ribosomal protein L8 6132 12.71 0.038 Only in cancer 0.024
S100A8 S100 calcium binding protein A8 6279 1.97 0.043 1.58 0.029
S100A9 S100 calcium binding protein A9 6280 1.90 0.034 1.66 0.007
GPX1 Glutathione peroxidase 1 2876 −1.38 0.008 −1.20 0.020
TNS1 Tensin 1 7145 −2.93 0.001 −1.59 0.035
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Six of these proteins had a higher abundance in cancer patients than in healthy controls
(RNF213/ring finger protein 213; CTSG/cathepsin G; PGLYRP1/peptidoglycan recogni-
tion protein 1; RPL8/ribosomal protein L8; S100A8/S100 calcium binding protein A8;
S100A9/S100 calcium binding protein A9). Two proteins were found at higher levels
in healthy controls (GPX1/glutathione peroxidase 1; TNS1/tensin 1). Two additional
proteins, AMDHD2/amidohydrolase domain-containing 2 and ERAP1/endoplasmic retic-
ulum aminopeptidase 1, were significantly differential in both studies, but with opposite
directions of change. Therefore, RNF213, CTSG, PGLYRP1, RPL8, S100A8, S100A9, GPX1
and TNS1 were identified as promising cancer-associated proteins which may provide
non-invasive cancer biomarkers.
3. Discussion
In the current study, we demonstrate that the platelet proteome of patients may be
affected by cancer presence and cancer therapy. Using these data in combination with
a previous cancer platelet proteomics dataset [28], we defined eight platelet proteins
(RNF213, CTSG, PGLYRP1, RPL8, S100A8, S100A9, GPX1 and TNS1) as promising cancer-
associated proteins that may provide, upon further validation, cancer biomarkers within
blood platelets.
The presence of an active malignancy influences multiple platelet parameters [27,28,31,32].
We previously showed that several platelet characteristics (e.g., count, volume, activation
status, and angiogenic/angiostatic content) are affected in early stages of cancer [27]. In
addition, a combination of these platelet features could be used to discriminate patients
with early-stage lung or pancreatic cancer from healthy sex- and age-matched controls.
In another independent study, the prospect of platelets as a potential source of cancer
biomarkers was also highlighted. In the latter study, it was demonstrated that changes in
platelet mRNA profiles could also be exploited to distinguish cancer patients from healthy
individuals [33,34].
While proteomics is often used in the search for potential cancer biomarkers in plasma
or serum, thus far, the platelet proteome has been largely overlooked, despite recent appli-
cations of proteomics in other diseases [35,36]. A proteomics study in tumor-bearing mice
demonstrated that platelets are able to sequester tumor-derived proteins from clinically
undetectable tumors [14]. Furthermore, we recently demonstrated for the first time that the
platelet proteome of cancer patients is already different from that of healthy individuals
in early stages of the disease, and normalizes after surgical resection of the tumor, thus
presenting a lucrative source for potential cancer biomarkers [28].
In the current study, we explored whether cancer-associated proteins could be iden-
tified in an independent group of nine patients with various types of malignancies (e.g.,
colon, rectal, anal, esophageal, gastric, tongue and primitive neuroectodermal cancer).
We found substantial changes in the platelet proteome of these patients compared to
healthy controls. We identified a total of 4059 unique proteins in platelets. Amongst these
proteins, 50 proteins were found at levels that were more than 1.5-fold higher in cancer
patients, while 36 proteins were more than 1.5-fold higher in healthy volunteers. These
numbers are highly comparable to data from our previous study in which we identified
4384 non-redundant proteins, of which 61 were more abundant in platelets of patients with
early-stage lung or pancreatic cancer, and 24 proteins being more abundant in platelets
of healthy controls [28]. The proteins that had markedly increased levels in platelets of
patients are mostly associated with inflammatory and immune responses. We realize that
the differences in median age of patients and controls and the use of comedication, as
well as the various tumor types in patients, might influence protein content of platelets.
Therefore, one should be careful with drawing conclusions, especially due to the small
number of patients. The current number of patients is too small to study a correlation with
tumor type. We did, however, see a potential tumor-type dependent change in the platelet
proteome in our previous study (pancreatic versus lung cancer) [28].
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These results are in agreement with previous studies performed in animals and
humans which demonstrate that a malignant tumor triggers such responses in the host
body [37]. Proteins that are more abundant in platelets of patients are produced or taken
up by megakaryocytes from which they are derived, or taken up from circulation by
platelets themselves. Megakaryocytes [38] and platelets [14] are both able to sequester
(tumor-derived) proteins from their microenvironment which could affect their proteome.
Megakaryocyte functions can also be influenced or hijacked by cytokines and interleukins
that are produced by tumors, affecting megakaryopoiesis and platelet content [39,40].
In the present study, we also explored the effect of antitumor treatment on the platelet
proteome of patients, which profoundly changed after initiation of treatment. Analysis
of matched samples of three patients, collected before and after drug administration,
revealed 432 proteins to be more abundant and 189 proteins to be less abundant after
starting intervention. The proteins exhibiting higher levels on-treatment were linked to
anabolic functions that are in line with a (re)active state of the megakaryocyte/platelet
compartment, as well as regulation of apoptosis. Proteins that were more abundant pre-
treatment were associated with mitochondrial organization and function. It is known
that most cytotoxic drugs exert their effect by inducing apoptosis, immunological cell
death, or other non-apoptotic cell deaths such as mitotic catastrophe, senescence and
autophagy [41–43]. As a consequence, the cellular and/or host response is to increase
processes such as protein translation, transport and biosynthesis [44,45]. Furthermore,
previous studies have shown that cancer therapy can affect mitochondrial function [46–49].
In addition, it was demonstrated that platelet dysfunction in thrombocytopenic patients
who were undergoing chemotherapy was due to impaired mitochondrial functioning [50].
In our study, the protein profiles within platelets appear to reflect the effect of cancer
therapy. These alterations could be due to a direct effect of the therapy on platelets.
However, it could also reflect the response of the body and/or the tumor to the treatment.
We are aware of the fact that it is difficult to draw thorough conclusions from this small
number of patients consisting of a variety of tumor types and receiving different antitumor
treatment regimens. More extensive research is therefore required.
Based on the comparison of our current data with our prior platelet proteomics
study [28], we identified eight cancer-associated proteins within platelets. In both studies,
six proteins were detected at levels that were more than 1.5-fold higher in platelets of
cancer patients than in healthy controls, and two proteins had more than 1.5-fold lower
levels. The pertinent proteins are known to be involved in cancer development and pro-
gression. RNF213 encodes an E3 ubiquitin-protein ligase that is known to degrade NFAT1,
a transcription factor that can in turn activate MDM2 to promote p53 degradation [51,52].
RNF213 is also important in tumor survival in hypoxic environments, and has been shown
to be mutated in several cancer types [53–55]. CTSG is a potent platelet activator [56] and
an endoprotease which has a role in cell migration, in eliminating intracellular pathogens,
and in the breakdown of tissues at inflammatory sites [57]. CTSG is also highly expressed in
various cancer types and is associated with tumor angiogenesis and metastasis [57–59]. PG-
LYRP1 is part of the innate immune system and has a direct antibacterial effect. It can also
induce cytotoxic activity against tumor cells by activating NK cells and T lymphocytes [60].
S100A8 and S100A9 are calcium-binding proteins that normally occur as heterodimers [61]
known as calprotectin [62]. They are known for their role in inflammatory responses and
cancer [63,64] and are proposed as potential cancer biomarkers [65–67]. RPL8, a ribosomal
protein involved in protein synthesis, is significantly overexpressed in various types of
tumor cells and is a predictor of clinical outcomes in patients with cancer [68]. In contrast to
the above six proteins, GPX1 and TNS1 were both found at a lower abundancy in platelets
of cancer patients. GPX1 is one of the most important antioxidant enzymes in humans.
Loss of its expression is reported in tumor samples of cancer patients, and downregula-
tion appears to correlate with poor prognosis [69–72]. TNS1 is involved in cell adhesion,
binding actin filaments and regulating actin polymerization. It is also important in malig-
nant diseases, enhancing tumor suppressor RhoA [73]. Interestingly, three proteins of the
Int. J. Mol. Sci. 2021, 22, 8236 11 of 16
proteins found in this study (RNF213, RPL8, GPX1) were also discovered as differentially
expressed in a study in which platelet mRNA of cancer patients was compared to that of
healthy individuals [33]. In future research, studies are warranted in larger numbers of
patients to validate our results in order to translate these to the clinics. In addition, it will be
of interest to study whether changes in platelets could be exploited in a predictive setting to
distinguish responders from non-responders. Other clinical decision parameters, including
the risk of treatment-related complications, such as bleeding or thrombosis, could possibly
be substantiated on the basis of platelet proteome profiles as well.
In conclusion, the current study shows that the platelet proteome may be affected by
cancer presence and antitumor therapy. In addition, eight cancer-associated proteins within
platelets were defined that were also identified in our previous study. Future research is
needed to further validate our current findings and to investigate whether platelets can
be used as a repository of diagnostic and/or predictive cancer biomarkers. This study
highlights the potential of blood platelets as a rich source of information that should be
explored in further biomarker research.
4. Materials and Methods
4.1. Healthy Volunteers and Patients
In accordance with the declaration of Helsinki, study approval was obtained from the
institutional review board of Amsterdam UMC. After informed consent was obtained, ten
milliliters of blood was collected from ten healthy volunteers and nine cancer patients.
The patients that were selected were newly diagnosed with cancer and prior to
the start of antitumor treatment, or had progressive disease following prior antitumor
treatment. Subject details are shown in Table 1. From three patients, a second blood
sample was collected at least one month after the start of antitumor treatment consisting of
chemotherapy, or chemotherapy in combination with surgery and/or radiotherapy.
4.2. Platelet Isolation and Lysis
A schematic overview of the workflow is shown in Figure 1. Freshly drawn blood
was collected by free-flow in 1/10 volume of 130 mM trisodium citrate. Platelet-rich
plasma (PRP) was prepared by centrifugation (156× g, 15 min, 20 ◦C). To prevent platelet
activation during further centrifugation, the pH of PRP was lowered to pH 6.5 by addition
of 0.1 volume ACD (2.5% trisodium citrate, 1.5% citric acid, 2% D-glucose). A platelet pellet
was obtained by centrifugation (330× g, 15 min, 20 ◦C). Next, the pellet was resuspended
in Hepes-Tyrode (HT) buffer (145 mM NaCl, 5 mM KCl, 0.5 mM Na2HPO4, 1 mM MgSO4,
10 mM Hepes, 5 mM D-glucose, pH 6.5) in approximately the same volume as the collected
PRP. Prostacyclin (PGI2, Cayman Chemical, Ann Arbor, MI, USA) was added to a final
concentration of 10 ng/mL to prevent aggregation. A platelet pellet was obtained by
centrifugation (330× g, 15 min, 20 ◦C). This washing step was repeated once. Platelets
were resuspended in HT buffer pH 7.3 (2 × 1011 platelets per liter). The tubes were then
centrifuged as above, in the presence of PGI2. Finally, the platelet pellet was resuspended in
100 µL sample buffer, heated for 5 min at 99 ◦C, and stored at −20 ◦C until further analysis.
4.3. Gel Electrophoresis and In-Gel Digestion
Precast 4–12% polyacrylamide gradient gels (NuPAGE, Fisher Scientific, Landsmeer,
The Netherlands) were used for all samples. Samples were corrected for platelet count and,
if necessary, diluted in sample buffer before loading a total of 25 µL on the gel. Proteins
were separated at 125 V and stained with Coomassie Brilliant Blue G-250 (Fisher Scientific,
Landsmeer, The Netherlands), washed in MilliQ water and stored at 4 ◦C until processing
by in-gel digestion.
Based on our benchmark study [74] and other clinical proteome studies including
platelet protemics of the past decade [28,75,76], we used in-gel digestion coupled to nanoLC-
MS/MS analysis and spectral counting as a robust and reproducible proteomics workflow.
After protein fractionation by gel electrophoresis, each lane on the gel was cut into ten gel
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slices. The gel slices were then cut into small cubes, and washed and dehydrated once in
50 mM ammonium bicarbonate (ABC) and twice in ABC containing 50% acetonitrile (ACN).
Subsequently, gel cubes were incubated for one hour at 56 ◦C in ABC containing 10 mM
dithiothreitol to break cysteine bonds, and for 45 min at room temperature (in the dark) in
ABC containing 50 mM iodoacetamide to alkylate cysteines. The cubes were subsequently
washed with ABC and ABC/50% ACN, dried in a vacuum centrifuge and incubated
overnight at 23 ◦C with 6.25 ng/mL sequencing-grade modified trypsin (Promega, Leiden,
The Netherlands). Extraction of peptides was performed once in 1% formic acid and twice
in 5% formic acid/50% ACN. Prior to LC-MS/MS analysis, ACN was evaporated, and the
extract volume reduced to 50 µL, in a vacuum centrifuge.
4.4. NanoLC-MS/MS
LC-MS/MS analysis was performed with an Ultimate 3000 Nano LC system (Dionex
LC-Packings, Amsterdam, The Netherlands) coupled online to a Q Exactive mass spec-
trometer (Thermo Fisher, Bremen, Germany). See also Piersma et al. [17]
NanoLC. The binary buffer system consisted of buffer A (0.5% acetic acid), and buffer
B (80% acetonitrile, 0.5% acetic acid). Following sample injection by the autosampler,
peptides were trapped on a 10 mm, 100 µm ID trap column (5 µm, 120 Å ReproSil Pur
C18aqua particles: (Dr Maisch GMBH, Ammerbuch-Entringen, Germany); 2% buffer B; 6
µL/min) and separated in 90 min over a 20-cm, 75-µm ID column (3 µm, 120 Å ReproSil
Pur C18 aqua particles; 10–40% buffer B gradent; 300 nL/min). The inject-to-inject cycle
was 120 min.
MS/MS. Peptides eluting from the column were ionized at 2 kV and sprayed into
the mass spectrometer. Full survey MS scans in the orbitrap of the apparatus recorded
accurate masses and intensities of intact peptides (resolution 70,000 at m/z 200, Automatic
Gain Control target value of 3 × 106 charges). The top 10 peptide ions with the highest
intensity (excluding singly charged ions) were selected for isolation and fragmentation in
the Higher-energy Collissional Dissociation cell of the apparatus (4 amu isolation width,
25% normalized collision energy). MS/MS spectra of the resulting fragments were recorded
in the orbitrap (resolution 17,500 at m/z 200, AGC target value of 2 × 105 charges, underfill
ratio of 0.1%). For top 10 selection of peptides, a dynamic exclusion rule was applied with
a repeat count of 1 and an exclusion time of 30 s.
4.5. Protein Identification
Database searching was performed with MaxQuant version 1.4.1.2. as described in
Piersma et al. [17], using a Uniprot human reference proteome FASTA file (2014_01 with
fragments removed, 61,552 entries). Searches were made specific for trypsin, allowing
two missed cleavages, as well as methionine oxidation and N-terminal acetylation as
variable modifications. Cysteine carboxamidomethylation resulting from iodoacetamide
treatment of samples was required as a fixed modification. Searching used mass deviation
windows of 4.5 ppm and 20 ppm for MS (intact peptides) and MS/MS (fragmented
peptides), respectively. We required a minimal peptide length of 7 amino acids, a minimal
Andromeda score for modified peptides of 40, and a minimum delta score (with respect
to the second hit) of 6. Using a decoy database strategy, the false discovery rate for both
peptide and protein identification was set at 1%. Multiple protein candidates that could
not be discriminated on the basis of MS/MS evidence were combined into protein groups.
Quantification was label-free. The mass spectrometry data have been submitted to the
ProteomeXchange Consortium via the PRIDE partner repository [77] with the dataset
identifier PXD010380.
4.6. Data Analysis
Proteins were quantified by spectral counting, that is, the number of identified MS/MS
spectra for a given protein [29]. Raw counts were normalized on the sum of spectral counts
for all identified proteins in a particular sample, relative to the average sample sum
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determined with all samples. Zero values were treated as protein expression values and
not imputed. Beta-binominal statistics were used to assess changes in protein levels in
platelet proteomes of healthy volunteers versus patients with cancer [78]. Paired statistics
was used to compare the pretreatment samples to matched samples collected after the
start of antitumor treatment [79]. The statistical tests were designed to take into account
technical variation of spectral count data and implemented in the R package count data.
Additional general protein information was retrieved by Ingenuity Pathway Analysis
(Ingenuity® Systems, www.ingenuity.com). Protein–protein associations were retrieved
from the STRING database (www.string-dg.org, version 10) [30] and loaded as a network
into Cytoscape (www.cytoscape.org) [80]. Highly connected protein clusters were identified
with the Cytoscape plug-in ClusterONE [81] and gene ontology analysis was performed
with the BINGO plug-in [82].
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/ijms22158236/s1.
Author Contributions: Conceptualization: M.W., S.S., I.d.R., H.D., H.J.B., H.M.W.V., C.R.J.; method-
ology: M.W., S.S., J.C.K., H.D., I.d.R., S.R.P., T.V.P., H.J.B., H.M.W.V., C.R.J.; software: J.C.K., S.R.P.,
T.V.P., C.R.J.; validation: M.W., S.S., J.C.K., S.R.P., T.V.P., A.W.G., M.O.E., H.M.W.V., C.R.J.; formal
analysis: J.C.K., S.R.P., T.V.P., C.R.J.; investigation: M.W., S.S., J.C.K., I.d.R., H.D., S.R.P., T.V.P.; re-
sources: A.W.G., M.O.E., H.M.W.V., C.R.J.; data curation: M.W., S.S., J.C.K., S.R.P., T.V.P., C.R.J.;
writing—original draft preparation: M.W., S.S., J.C.K., H.M.W.V., C.R.J.; writing—review and editing:
M.W., S.S., A.W.G., M.O.E., H.M.W.V., C.R.J.; visualization: M.W., S.S., J.C.K., H.D., I.d.R., S.R.P.,
T.V.P., H.M.W.V., C.R.J.; supervision: H.M.W.V., C.R.J.; project administration: M.W., S.S., H.M.W.V.,
C.R.J. All authors have read and agreed to the published version of the manuscript.
Funding: The Dutch Cancer Foundation (UU2008-4241) and an AEGON scholarship (to M.W.) and
The Kootstra Talent Fellowship (CD.18.0008) (to S.S.).
Institutional Review Board Statement: In accordance with the declaration of Helsinki, study ap-
proval was obtained from the institutional review board of Amsterdam UMC (protocol code 2018.543,
date of approval 9 January 2019).
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Acknowledgments: This work was financially supported by the Dutch Cancer Foundation and an
AEGON scholarship (to MW) and The Kootstra Talent Fellowship (to SS). Cancer Center Amsterdam
is acknowledged for support of the proteomics infrastructure.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. DeSantis, C.E.; Lin, C.C.; Mariotto, A.B.; Siegel, R.L.; Stein, K.D.; Kramer, J.L.; Alteri, R.; Robbins, A.S.; Jemal, A. Cancer treatment
and survivorship statistics, 2014. CA Cancer J. Clin. 2014, 64, 252–271. [CrossRef]
2. Diamandis, E.P. Towards identification of true cancer biomarkers. BMC Med. 2014, 12, 156. [CrossRef]
3. Alix-Panabières, C.; Pantel, K. Challenges in circulating tumour cell research. Nat. Rev. Cancer 2014, 14, 623–631. [CrossRef]
4. Bettegowda, C.; Sausen, M.; Leary, R.J.; Kinde, I.; Wang, Y.; Agrawal, N.; Bartlett, B.R.; Wang, H.; Luber, B.; Alani, R.M.; et al.
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6, 224ra224. [CrossRef]
5. Sabrkhany, S.; Kuijpers, M.J.; Verheul, H.M.; Griffioen, A.W.; oude Egbrink, M.G. Platelets: An unexploited data source in
biomarker research. Lancet Haematol. 2015, 2, e512–e513. [CrossRef]
6. Sabrkhany, S.; Kuijpers, M.J.E.; Griffioen, A.W.; Oude Egbrink, M.G.A. Platelets: The holy grail in cancer blood biomarker
research? Angiogenesis 2018, 22, 1–2. [CrossRef]
7. Versteeg, H.H.; Heemskerk, J.W.; Levi, M.; Reitsma, P.H. New fundamentals in hemostasis. Physiol. Rev. 2013, 93, 327–358.
[CrossRef]
8. Koupenova, M.; Clancy, L.; Corkrey, H.A.; Freedman, J.E. Circulating Platelets as Mediators of Immunity, Inflammation, and
Thrombosis. Circ. Res. 2018, 122, 337–351. [CrossRef] [PubMed]
9. Sabrkhany, S.; Griffioen, A.W.; Oude Egbrink, M.G. The role of blood platelets in tumor angiogenesis. Biochim. Biophys. Acta 2011,
1815, 189–196. [CrossRef] [PubMed]
10. Verheul, H.M.; Hoekman, K.; Luykx-de Bakker, S.; Eekman, C.A.; Folman, C.C.; Broxterman, H.J.; Pinedo, H.M. Platelet:
Transporter of vascular endothelial growth factor. Clin. Cancer Res. 1997, 3, 2187–2190.
11. Gay, L.J.; Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 2011, 11, 123–134. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 8236 14 of 16
12. Sabrkhany, S.; Kuijpers, M.J.E.; Oude Egbrink, M.G.A.; Griffioen, A.W. Platelets as messengers of early-stage cancer. Cancer
Metastasis Rev. 2021. [CrossRef]
13. Burkhart, J.M.; Vaudel, M.; Gambaryan, S.; Radau, S.; Walter, U.; Martens, L.; Geiger, J.; Sickmann, A.; Zahedi, R.P. The first
comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural
and functional pathways. Blood 2012, 120, e73–e82. [CrossRef]
14. Klement, G.L.; Yip, T.T.; Cassiola, F.; Kikuchi, L.; Cervi, D.; Podust, V.; Italiano, J.E.; Wheatley, E.; Abou-Slaybi, A.; Bender, E.; et al.
Platelets actively sequester angiogenesis regulators. Blood 2009, 113, 2835–2842. [CrossRef]
15. Verheul, H.M.; Lolkema, M.P.; Qian, D.Z.; Hilkes, Y.H.; Liapi, E.; Akkerman, J.W.; Pili, R.; Voest, E.E. Platelets take up the
monoclonal antibody bevacizumab. Clin. Cancer Res. 2007, 13, 5341–5347. [CrossRef]
16. Sabrkhany, S.; Griffioen, A.W.; Pineda, S.; Sanders, L.; Mattheij, N.; van Geffen, J.P.; Aarts, M.J.; Heemskerk, J.W.; Oude Egbrink,
M.G.; Kuijpers, M.J. Sunitinib uptake inhibits platelet function in cancer patients. Eur. J. Cancer 2016, 66, 47–54. [CrossRef]
[PubMed]
17. Piersma, S.R.; Broxterman, H.J.; Kapci, M.; de Haas, R.R.; Hoekman, K.; Verheul, H.M.; Jiménez, C.R. Proteomics of the
TRAP-induced platelet releasate. J. Proteom. 2009, 72, 91–109. [CrossRef]
18. Kisucka, J.; Butterfield, C.E.; Duda, D.G.; Eichenberger, S.C.; Saffaripour, S.; Ware, J.; Ruggeri, Z.M.; Jain, R.K.; Folkman, J.;
Wagner, D.D. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc. Natl. Acad. Sci.
USA 2006, 103, 855–860. [CrossRef]
19. Ho-Tin-Noe, B.; Goerge, T.; Cifuni, S.M.; Duerschmied, D.; Wagner, D.D. Platelet granule secretion continuously prevents
intratumor hemorrhage. Cancer Res. 2008, 68, 6851–6858. [CrossRef]
20. Cho, M.S.; Bottsford-Miller, J.; Vasquez, H.G.; Stone, R.; Zand, B.; Kroll, M.H.; Sood, A.K.; Afshar-Kharghan, V. Platelets increase
the proliferation of ovarian cancer cells. Blood 2012, 120, 4869–4872. [CrossRef]
21. Carr, B.I.; Cavallini, A.; D’Alessandro, R.; Refolo, M.G.; Lippolis, C.; Mazzocca, A.; Messa, C. Platelet extracts induce growth,
migration and invasion in human hepatocellular carcinoma in vitro. BMC Cancer 2014, 14, 43. [CrossRef] [PubMed]
22. Labelle, M.; Begum, S.; Hynes, R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like
transition and promotes metastasis. Cancer Cell 2011, 20, 576–590. [CrossRef] [PubMed]
23. Labelle, M.; Begum, S.; Hynes, R.O. Platelets guide the formation of early metastatic niches. Proc. Natl. Acad. Sci. USA 2014, 111,
E3053–E3061. [CrossRef]
24. Cervi, D.; Yip, T.T.; Bhattacharya, N.; Podust, V.N.; Peterson, J.; Abou-Slaybi, A.; Naumov, G.N.; Bender, E.; Almog, N.; Italiano,
J.E., Jr.; et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008, 111, 1201–1207. [CrossRef]
25. Zaslavsky, A.; Baek, K.H.; Lynch, R.C.; Short, S.; Grillo, J.; Folkman, J.; Italiano, J.E., Jr.; Ryeom, S. Platelet-derived thrombospondin-
1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 2010, 115, 4605–4613. [CrossRef]
26. Lin, R.J.; Afshar-Kharghan, V.; Schafer, A.I. Paraneoplastic thrombocytosis: The secrets of tumor self-promotion. Blood 2014, 124,
184–187. [CrossRef]
27. Sabrkhany, S.; Kuijpers, M.J.E.; van Kuijk, S.M.J.; Sanders, L.; Pineda, S.; Olde Damink, S.W.M.; Dingemans, A.C.; Griffioen, A.W.;
Oude Egbrink, M.G.A. A combination of platelet features allows detection of early-stage cancer. Eur. J. Cancer 2017, 80, 5–13.
[CrossRef]
28. Sabrkhany, S.; Kuijpers, M.J.E.; Knol, J.C.; Olde Damink, S.W.M.; Dingemans, A.C.; Verheul, H.M.; Piersma, S.R.; Pham, T.V.;
Griffioen, A.W.; Oude Egbrink, M.G.A.; et al. Exploration of the platelet proteome in patients with early-stage cancer. J. Proteom.
2018, 177, 65–74. [CrossRef]
29. Liu, H.; Sadygov, R.G.; Yates, J.R. A model for random sampling and estimation of relative protein abundance in shotgun
proteomics. Anal. Chem. 2004, 76, 4193–4201. [CrossRef]
30. Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta-Cepas, J.; Simonovic, M.; Roth, A.; Santos, A.;
Tsafou, K.P.; et al. STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015, 43,
D447–D452. [CrossRef]
31. Peterson, J.E.; Zurakowski, D.; Italiano, J.E., Jr.; Michel, L.V.; Connors, S.; Oenick, M.; D’Amato, R.J.; Klement, G.L.; Folkman, J.
VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 2012, 15, 265–273. [CrossRef]
32. Nilsson, R.J.; Balaj, L.; Hulleman, E.; van Rijn, S.; Pegtel, D.M.; Walraven, M.; Widmark, A.; Gerritsen, W.R.; Verheul, H.M.;
Vandertop, W.P.; et al. Blood platelets contain tumor-derived RNA biomarkers. Blood 2011, 118, 3680–3683. [CrossRef]
33. Best, M.G.; Sol, N.; Kooi, I.; Tannous, J.; Westerman, B.A.; Rustenburg, F.; Schellen, P.; Verschueren, H.; Post, E.; Koster, J.; et al.
RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.
Cancer Cell 2015, 28, 666–676. [CrossRef]
34. Best, M.G.; Sol, N.; Sjors, G.J.G.; Vancura, A.; Muller, M.; Niemeijer, A.N.; Fejes, A.V.; Tjon Kon Fat, L.A.; Huis, A.E.; Leurs, C.;
et al. Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. Cancer Cell 2017,
32, 238–252.e239. [CrossRef] [PubMed]
35. Looße, C.; Swieringa, F.; Heemskerk, J.W.M.; Sickmann, A.; Lorenz, C. Platelet proteomics: From discovery to diagnosis. Expert
Rev. Proteom. 2018, 15, 467–476. [CrossRef] [PubMed]
36. García, Á. Platelet clinical proteomics: Facts, challenges, and future perspectives. Proteom. Clin. Appl. 2016, 10, 767–773. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2021, 22, 8236 15 of 16
37. Gajewski, T.F.; Schreiber, H.; Fu, Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013, 14,
1014–1022. [CrossRef]
38. Heijnen, H.F.; Debili, N.; Vainchencker, W.; Breton-Gorius, J.; Geuze, H.J.; Sixma, J.J. Multivesicular bodies are an intermediate
stage in the formation of platelet alpha-granules. Blood 1998, 91, 2313–2325. [CrossRef]
39. Buergy, D.; Wenz, F.; Groden, C.; Brockmann, M.A. Tumor-platelet interaction in solid tumors. Int. J. Cancer 2012, 130, 2747–2760.
[CrossRef]
40. Stone, R.L.; Nick, A.M.; McNeish, I.A.; Balkwill, F.; Han, H.D.; Bottsford-Miller, J.; Rupairmoole, R.; Armaiz-Pena, G.N.; Pecot,
C.V.; Coward, J.; et al. Paraneoplastic thrombocytosis in ovarian cancer. N. Engl. J. Med. 2012, 366, 610–618. [CrossRef]
41. Notte, A.; Leclere, L.; Michiels, C. Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem. Pharm. 2011,
82, 427–434. [CrossRef] [PubMed]
42. Gebremeskel, S.; Johnston, B. Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: Impact on
clinical studies and considerations for combined therapies. Oncotarget 2015, 6, 41600–41619. [CrossRef]
43. Ricci, M.S.; Zong, W.X. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 2006, 11, 342–357. [CrossRef]
44. Wiita, A.P.; Ziv, E.; Wiita, P.J.; Urisman, A.; Julien, O.; Burlingame, A.L.; Weissman, J.S.; Wells, J.A. Global cellular response to
chemotherapy-induced apoptosis. eLife 2013, 2, e01236. [CrossRef] [PubMed]
45. Cohen, A.A.; Geva-Zatorsky, N.; Eden, E.; Frenkel-Morgenstern, M.; Issaeva, I.; Sigal, A.; Milo, R.; Cohen-Saidon, C.; Liron, Y.;
Kam, Z.; et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 2008, 322, 1511–1516. [CrossRef]
46. Van Gisbergen, M.W.; Voets, A.M.; Starmans, M.H.; de Coo, I.F.; Yadak, R.; Hoffmann, R.F.; Boutros, P.C.; Smeets, H.J.; Dubois, L.;
Lambin, P. How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges,
opportunities and models. Mutat. Res. Rev. Mutat. Res. 2015, 764, 16–30. [CrossRef]
47. Bracci, L.; Schiavoni, G.; Sistigu, A.; Belardelli, F. Immune-based mechanisms of cytotoxic chemotherapy: Implications for the
design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014, 21, 15–25. [CrossRef]
48. Kang, D.H.; Weaver, M.T.; Park, N.J.; Smith, B.; McArdle, T.; Carpenter, J. Significant impairment in immune recovery after cancer
treatment. Nurs. Res. 2009, 58, 105–114. [CrossRef]
49. Emens, L.A.; Middleton, G. The interplay of immunotherapy and chemotherapy: Harnessing potential synergies. Cancer Immunol.
Res. 2015, 3, 436–443. [CrossRef] [PubMed]
50. Baaten, C.C.F.M.; Moenen, F.C.J.I.; Henskens, Y.M.C.; Swieringa, F.; Wetzels, R.J.H.; van Oerle, R.; Heijnen, H.F.G.; Ten Cate, H.;
Holloway, G.P.; Beckers, E.A.M.; et al. Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer
patients undergoing chemotherapy. Haematologica 2018, 103, 1557–1567. [CrossRef] [PubMed]
51. Scholz, B.; Korn, C.; Wojtarowicz, J.; Mogler, C.; Augustin, I.; Boutros, M.; Niehrs, C.; Augustin, H.G. Endothelial RSPO3 Controls
Vascular Stability and Pruning through Non-canonical WNT/Ca2+/NFAT Signaling. Dev. Cell 2016, 36, 79–93. [CrossRef]
[PubMed]
52. Zhang, X.; Zhang, Z.; Cheng, J.; Li, M.; Wang, W.; Xu, W.; Wang, H.; Zhang, R. Transcription factor NFAT1 activates the mdm2
oncogene independent of p53. J. Biol. Chem. 2012, 287, 30468–30476. [CrossRef] [PubMed]
53. Li, X.; Xu, W.; Kang, W.; Wong, S.H.; Wang, M.; Zhou, Y.; Fang, X.; Zhang, X.; Yang, H.; Wong, C.H.; et al. Genomic analysis of
liver cancer unveils novel driver genes and distinct prognostic features. Theranostics 2018, 8, 1740–1751. [CrossRef]
54. Ge, S.; Li, B.; Li, Y.; Li, Z.; Liu, Z.; Chen, Z.; Wu, J.; Gao, J.; Shen, L. Genomic alterations in advanced gastric cancer endoscopic
biopsy samples using targeted next-generation sequencing. Am. J. Cancer Res. 2017, 7, 1540–1553.
55. Banh, R.S.; Iorio, C.; Marcotte, R.; Xu, Y.; Cojocari, D.; Rahman, A.A.; Pawling, J.; Zhang, W.; Sinha, A.; Rose, C.M.; et al. PTP1B
controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia. Nat. Cell
Biol. 2016, 18, 803–813. [CrossRef]
56. Sambrano, G.R.; Huang, W.; Faruqi, T.; Mahrus, S.; Craik, C.; Coughlin, S.R. Cathepsin G activates protease-activated receptor-4
in human platelets. J. Biol. Chem. 2000, 275, 6819–6823. [CrossRef] [PubMed]
57. Tan, G.J.; Peng, Z.K.; Lu, J.P.; Tang, F.Q. Cathepsins mediate tumor metastasis. World J. Biol. Chem. 2013, 4, 91–101. [CrossRef]
58. Kuester, D.; Lippert, H.; Roessner, A.; Krueger, S. The cathepsin family and their role in colorectal cancer. Pathol. Res. Pract. 2008,
204, 491–500. [CrossRef]
59. Wilson, T.J.; Nannuru, K.C.; Futakuchi, M.; Singh, R.K. Cathepsin G-mediated enhanced TGF-beta signaling promotes angiogene-
sis via upregulation of VEGF and MCP-1. Cancer Lett. 2010, 288, 162–169. [CrossRef]
60. Sharapova, T.N.; Ivanova, O.K.; Soshnikova, N.V.; Romanova, E.A.; Sashchenko, L.P.; Yashin, D.V. Innate Immunity Protein Tag7
Induces 3 Distinct Populations of Cytotoxic Cells That Use Different Mechanisms to Exhibit Their Antitumor Activity on Human
Leukocyte Antigen-Deficient Cancer Cells. J. Innate Immun. 2017, 9, 598–608. [CrossRef]
61. Korndörfer, I.P.; Brueckner, F.; Skerra, A. The crystal structure of the human (S100A8/S100A9)2 heterotetramer, calprotectin,
illustrates how conformational changes of interacting alpha-helices can determine specific association of two EF-hand proteins.
J. Mol. Biol. 2007, 370, 887–898. [CrossRef]
62. Yui, S.; Nakatani, Y.; Mikami, M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad
apoptosis-inducing activity. Biol. Pharm. Bull. 2003, 26, 753–760. [CrossRef]
63. Markowitz, J.; Carson, W.E. Review of S100A9 biology and its role in cancer. Biochim. Biophys. Acta 2013, 1835, 100–109. [CrossRef]
64. Srikrishna, G. S100A8 and S100A9: New insights into their roles in malignancy. J. Innate Immun. 2012, 4, 31–40. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 8236 16 of 16
65. Kim, H.J.; Kang, H.J.; Lee, H.; Lee, S.T.; Yu, M.H.; Kim, H.; Lee, C. Identification of S100A8 and S100A9 as serological markers for
colorectal cancer. J. Proteome Res. 2009, 8, 1368–1379. [CrossRef] [PubMed]
66. Hermani, A.; Hess, J.; De Servi, B.; Medunjanin, S.; Grobholz, R.; Trojan, L.; Angel, P.; Mayer, D. Calcium-binding proteins S100A8
and S100A9 as novel diagnostic markers in human prostate cancer. Clin. Cancer Res. 2005, 11, 5146–5152. [CrossRef]
67. Sun, W.; Xing, B.; Guo, L.; Liu, Z.; Mu, J.; Sun, L.; Wei, H.; Zhao, X.; Qian, X.; Jiang, Y.; et al. Quantitative Proteomics Analysis of
Tissue Interstitial Fluid for Identification of Novel Serum Candidate Diagnostic Marker for Hepatocellular Carcinoma. Sci. Rep.
2016, 6, 26499. [CrossRef]
68. Dolezal, J.M.; Dash, A.P.; Prochownik, E.V. Diagnostic and prognostic implications of ribosomal protein transcript expression
patterns in human cancers. BMC Cancer 2018, 18, 275. [CrossRef] [PubMed]
69. Min, S.Y.; Kim, H.S.; Jung, E.J.; Jee, C.D.; Kim, W.H. Prognostic significance of glutathione peroxidase 1 (GPX1) down-regulation
and correlation with aberrant promoter methylation in human gastric cancer. Anticancer Res. 2012, 32, 3169–3175. [PubMed]
70. Jerome-Morais, A.; Wright, M.E.; Liu, R.; Yang, W.; Jackson, M.I.; Combs, G.F.; Diamond, A.M. Inverse association between
glutathione peroxidase activity and both selenium-binding protein 1 levels and Gleason score in human prostate tissue. Prostate
2012, 72, 1006–1012. [CrossRef]
71. Han, J.J.; Xie, D.R.; Wang, L.L.; Liu, Y.Q.; Wu, G.F.; Sun, Q.; Chen, Y.X.; Wei, Y.; Huang, Z.Q.; Li, H.G. Significance of glutathione
peroxidase 1 and caudal-related homeodomain transcription factor in human gastric adenocarcinoma. Gastroenterol. Res. Pract.
2013, 2013, 380193. [CrossRef]
72. Metere, A.; Frezzotti, F.; Graves, C.E.; Vergine, M.; De Luca, A.; Pietraforte, D.; Giacomelli, L. A possible role for selenoprotein
glutathione peroxidase (GPx1) and thioredoxin reductases (TrxR1) in thyroid cancer: Our experience in thyroid surgery. Cancer
Cell Int. 2018, 18, 7. [CrossRef]
73. Shih, Y.P.; Sun, P.; Wang, A.; Lo, S.H. Tensin1 positively regulates RhoA activity through its interaction with DLC1. Biochim.
Biophys. Acta 2015, 1853, 3258–3265. [CrossRef] [PubMed]
74. Piersma, S.R.; Fiedler, U.; Span, S.; Lingnau, A.; Pham, T.V.; Hoffmann, S.; Kubbutat, M.H.; Jiménez, C.R. Workflow comparison
for label-free, quantitative secretome proteomics for cancer biomarker discovery: Method evaluation, differential analysis, and
verification in serum. J. Proteome Res. 2010, 9, 1913–1922. [CrossRef] [PubMed]
75. Wojtuszkiewicz, A.; Schuurhuis, G.J.; Kessler, F.L.; Piersma, S.R.; Knol, J.C.; Pham, T.V.; Jansen, G.; Musters, R.J.; van Meerloo,
J.; Assaraf, Y.G.; et al. Exosomes Secreted by Apoptosis-Resistant Acute Myeloid Leukemia (AML) Blasts Harbor Regulatory
Network Proteins Potentially Involved in Antagonism of Apoptosis. Mol. Cell Proteom. 2016, 15, 1281–1298. [CrossRef]
76. Bosch, L.J.W.; de Wit, M.; Pham, T.V.; Coupé, V.M.H.; Hiemstra, A.C.; Piersma, S.R.; Oudgenoeg, G.; Scheffer, G.L.; Mongera, S.;
Sive Droste, J.T.; et al. Novel Stool-Based Protein Biomarkers for Improved Colorectal Cancer Screening: A Case-Control Study.
Ann. Intern. Med. 2017, 167, 855–866. [CrossRef] [PubMed]
77. Vizcaíno, J.A.; Csordas, A.; Del-Toro, N.; Dianes, J.A.; Griss, J.; Lavidas, I.; Mayer, G.; Perez-Riverol, Y.; Reisinger, F.; Ternent, T.;
et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016, 44, 11033. [CrossRef] [PubMed]
78. Pham, T.V.; Piersma, S.R.; Warmoes, M.; Jimenez, C.R. On the beta-binomial model for analysis of spectral count data in label-free
tandem mass spectrometry-based proteomics. Bioinformatics 2010, 26, 363–369. [CrossRef]
79. Pham, T.V.; Jimenez, C.R. An accurate paired sample test for count data. Bioinformatics 2012, 28, i596–i602. [CrossRef]
80. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A
software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13, 2498–2504. [CrossRef]
81. Nepusz, T.; Yu, H.; Paccanaro, A. Detecting overlapping protein complexes in protein-protein interaction networks. Nat. Methods
2012, 9, 471–472. [CrossRef]
82. Maere, S.; Heymans, K.; Kuiper, M. BiNGO: A Cytoscape plugin to assess overrepresentation of gene ontology categories in
biological networks. Bioinformatics 2005, 21, 3448–3449. [CrossRef]
